The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model

Urology

Volumn 85, Issue 1, 2015, Pages 273.e1-273.e7

  Zhang, Xiaohua ^a   Wang, Xianjin ^a   Qin, Liang ^a   Xu, Tianyuan ^a   Zhu, Zhaowei ^a   Zhong, Shan ^a   Zhang, Minguang ^a   Shen, Zhoujun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; DNA NUCLEOTIDYLEXOTRANSFERASE; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; VASCULOTROPIN; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PURINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOBLOTTING; MALE; MOUSE; NICK END LABELING; NONHUMAN; PC12 CELL LINE; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; ADRENAL GLAND NEOPLASMS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG SCREENING; RAT;

ADRENAL GLAND NEOPLASMS; ANIMALS; INDOLES; MICE; MICE, INBRED BALB C; MULTIPROTEIN COMPLEXES; PC12 CELLS; PHEOCHROMOCYTOMA; PURINES; RATS; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918784157     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.09.020     Document Type: Article

References (30)

1. J. Favier, P. Igaz, and N. Burnichon Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma Endocr Pathol 23 2012 34 42
2. A.J. Lowery, S. Walsh, and E.W. McDermott Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas Oncologist 18 2013 391 407
3. M.R. Druce, G.A. Kaltsas, and M. Fraenkel Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) Horm Metab Res 41 2009 697 702
4. C. Jimenez, E. Rohren, and M.A. Habra Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma Curr Oncol Rep 15 2013 356 371
5. R. Buzzoni, S. Pusceddu, and A. Damato Malignant pheochromocytoma and paraganglioma: future considerations for therapy Q J Nucl Med Mol Imaging 57 2013 153 160
6. G. Parenti, B. Zampetti, and E. Rapizzi Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma J Oncol 2012 2012 872713
7. D. Benjamin, M. Colombi, C. Moroni, and M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
8. H. Okazaki, N. Matsunaga, and T. Fujioka Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma Cancer Res 74 2014 543 551
9. R. Pezzani, B. Rubin, and M. Redaelli The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells Endocr J 61 2014 41 53
10. P.J. Houghton Everolimus Clin Cancer Res 16 2010 1368 1372
11. D.A. Guertin, and D.M. Sabatini The pharmacology of mTOR inhibition Sci Signal 2 2009 pe24
12. C.C. Thoreen, and D.M. Sabatini Rapamycin inhibits mTORC1, but not completely Autophagy 5 2009 725 726
13. J.S. Carew, K.R. Kelly, and S.T. Nawrocki Mechanisms of mTOR inhibitor resistance in cancer therapy Targeted Oncol 6 2011 17 27
14. C.A. Sparks, and D.A. Guertin Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy Oncogene 29 2010 3733 3744
15. M.E. Feldman, B. Apsel, and A. Uotila Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 2009 e38
16. K. Yu, C. Shi, and L. Toral-Barza Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Res 70 2010 621 631
17. C.C. Thoreen, S.A. Kang, and J.W. Chang An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 2009 8023 8032
18. M.R. Janes, J.J. Limon, and L. So Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nat Med 16 2010 205 213
19. Y.J. Zhang, Y. Duan, and X.F. Zheng Targeting the mTOR kinase domain: the second generation of mTOR inhibitors Drug Discov Today 16 2011 325 331
20. H. Li, J. Lin, and X. Wang Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer Breast Cancer Res Treat 134 2012 1057 1066
21. J.K. Altman, A. Szilard, and D.J. Goussetis Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Clin Cancer Res 20 2014 2400 2409
22. N.J. Jordan, C.M. Dutkowski, and D. Barrow Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro Breast Cancer Res 16 2014 R12
23. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cel Biol 12 2011 21 35
24. D.A. Guertin, and D.M. Sabatini An expanding role for mTOR in cancer Trends Molecular Medicine 11 2005 353 361
25. C. Betz, and M.N. Hall Where is mTOR and what is it doing there? J Cell Biol 203 2013 563 574
26. S.Y. Sun mTOR kinase inhibitors as potential cancer therapeutic drugs Cancer Lett 340 2013 1 8
27. M. Laplante, and D.M. Sabatini mTOR signaling at a glance J Cel Sci 122 2009 3589 3594
28. F. Feng, Y. Zhu, and X. Wang Predictive factors for malignant pheochromocytoma: analysis of 136 patients J Urol 185 2011 1583 1590
29. Y. Saito, Y. Tanaka, and Y. Aita Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD Am J Physiol Endocrinol Metab 302 2012 E615 625
30. E. Motylewska, H. Lawnicka, and M. Kowalewicz-Kulbat Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro Endokrynol Pol 64 2013 368 374